245 related articles for article (PubMed ID: 9806393)
1. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.
Spanier TB; Chen JM; Oz MC; Edwards NM; Kisiel W; Stern DM; Rose EA; Schmidt AM
J Thorac Cardiovasc Surg; 1998 Nov; 116(5):860-9. PubMed ID: 9806393
[TBL] [Abstract][Full Text] [Related]
2. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.
Spanier TB; Oz MC; Minanov OP; Simantov R; Kisiel W; Stern DM; Rose EA; Schmidt AM
J Thorac Cardiovasc Surg; 1998 May; 115(5):1179-88. PubMed ID: 9605089
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
Bel A; Borik W; Davidson S; Helies JM; Stimmer L; Fremes S; Zelenkofske S; Rusconi C; Alexander J; Alexander D; Menasché P; Pepper J
Eur J Cardiothorac Surg; 2016 Feb; 49(2):682-9. PubMed ID: 25953802
[TBL] [Abstract][Full Text] [Related]
4. Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time.
Spanier TB; Oz MC; Madigan JD; Rose EA; Stern DM; Nowygrod R; Schmidt AM
ASAIO J; 1997; 43(5):M526-30. PubMed ID: 9360098
[TBL] [Abstract][Full Text] [Related]
5. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
[TBL] [Abstract][Full Text] [Related]
6. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons.
Gikakis N; Rao AK; Miyamoto S; Gorman JH; Khan MM; Anderson HL; Hack CE; Sun L; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1043-51. PubMed ID: 9832697
[TBL] [Abstract][Full Text] [Related]
8. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
9. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
[TBL] [Abstract][Full Text] [Related]
10. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1.
Kozek-Langenecker SA; Wanzel O; Berger R; Kettner SC; Coraim F
Anesth Analg; 1998 Nov; 87(5):985-8. PubMed ID: 9806669
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass.
Philippou H; Adami A; Davidson SJ; Pepper JR; Burman JF; Lane DA
Thromb Haemost; 2000 Jul; 84(1):124-8. PubMed ID: 10928482
[TBL] [Abstract][Full Text] [Related]
12. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
13. Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass.
Morizumi S; Hiramatsu Y; Matsuzaki K; Goto Y; Sato S; Abe M; Kato H; Matsubara M; Sakakibara Y
J Card Surg; 2014 Jan; 29(1):35-40. PubMed ID: 24266905
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
15. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
17. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
[TBL] [Abstract][Full Text] [Related]
18. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
[TBL] [Abstract][Full Text] [Related]
19. Factor IXa inhibitors as novel anticoagulants.
Howard EL; Becker KC; Rusconi CP; Becker RC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):722-7. PubMed ID: 17272750
[TBL] [Abstract][Full Text] [Related]
20. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass.
Chung JH; Gikakis N; Rao AK; Drake TA; Colman RW; Edmunds LH
Circulation; 1996 Jun; 93(11):2014-8. PubMed ID: 8640976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
